Local radiopharmaceutical production reduces therapy costs by 93% to 96% across 54 African nations
This systematic review and quantitative infrastructure analysis assesses the availability, accessibility, and economic feasibility of radionuclide therapies across 54 African nations. The review compares local production of I-131 and Lu-177-PSMA against imported agents. Data were drawn from 47 studies included in the analysis.
The analysis found that I-131 therapy for thyroid cancer is available in 28 out of 54 countries. In contrast, Lu-177-PSMA for prostate cancer is available in only 7 countries. These figures represent 51.9% and 13.0% availability rates respectively.
Economic analysis indicates that local production reduces therapy costs by 93% to 96%. For Lu-177-PSMA specifically, the cost ratio between local and imported agents is 1:28.3. Local costs range from US$1,500 to US$3,000 versus US$42,500 for imports. Physician density for nuclear medicine is 0.18 per million population compared to 3.1 in other contexts.
The authors conclude that targeted investment in cyclotron infrastructure and workforce development is urgently needed. Limitations regarding the review are not reported in the source text.